Tamoxifene E Patologia Genitale Femminile Correlata. Considerazioni Generali Ed Esperienza Clinica

N. De Frenza, G. Falco, A. Traversa, M. De Liso, G. Simone, V. Rubini, F. A. Zito

Research output: Contribution to journalArticlepeer-review


Tamoxifen (TAM) is a non-steroid triphenilethylene derivative wish estrogen agonist-antagonist properties. In oncology it is used the tumoristatic TAM-action. Nowadays, TAM is the elective treatment for post-menopausal patients with breast cancer and positive lymphnodes as well as for pre-menopausal patients with negative nodes and positive estrogen receptors. It's acknowlegded the efficiency of TAM in reducing the incidence of controlateral breast cancer up to a prevention use for high risk patients After an exhaustive bibliographical review, the Authors introduce their study about TAM-induced genital pathology in women with breast cancer. 52 patients were enrolled in this study, treated between 1996-1997 by the Dept. of Gynecology of the Cancer Institute of Bari. The results, according to the litterature, demonstrate that it should be better to follow closely the TAM-treated patients, moreover beginning with a preventive check of the «endometrial status» before the TAM-treatment and then to have periodic medical examinations to reduce to a minimum the risk of developing a even serious gynecologic TAM-correlated disease.

Original languageItalian
JournalGiornale Italiano di Ostetricia e Ginecologia
Issue number9
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this